Legal & General Group’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-60,658
| Closed | -$4.11M | – | 3404 |
|
|
2019
Q3 | $4.11M | Buy |
60,658
+48,435
| +396% | +$3.33M | ﹤0.01% | 1394 |
|
|
2019
Q2 | $711K | Buy |
12,223
+1,635
| +15% | +$96.9K | ﹤0.01% | 2064 |
|
|
2019
Q1 | $741K | Buy |
10,588
+89
| +0.8% | +$6.6K | ﹤0.01% | 2058 |
|
|
2018
Q4 | $677K | Buy |
10,499
+3,818
| +57% | +$268K | ﹤0.01% | 2029 |
|
|
2018
Q3 | $469K | Hold |
6,681
| – | – | ﹤0.01% | 2155 |
|
|
2018
Q2 | $337K | Sell |
6,681
-5,619
| -46% | -$223K | ﹤0.01% | 2197 |
|
|
2018
Q1 | $385K | Buy |
12,300
+4,968
| +68% | +$165K | ﹤0.01% | 2169 |
|
|
2017
Q4 | $252K | Hold |
7,332
| – | – | ﹤0.01% | 2249 |
|
|
2017
Q3 | $235K | Buy |
7,332
+400
| +6% | +$12.6K | ﹤0.01% | 2288 |
|
|
2017
Q2 | $226K | Buy |
6,932
+710
| +11% | +$22.5K | ﹤0.01% | 2261 |
|
|
2017
Q1 | $196K | Buy |
6,222
+2,038
| +49% | +$60.3K | ﹤0.01% | 2261 |
|
|
2016
Q4 | $124K | Buy |
4,184
+1,252
| +43% | +$38.2K | ﹤0.01% | 2431 |
|
|
2016
Q3 | $83K | Hold |
2,932
| – | – | ﹤0.01% | 2299 |
|
|
2016
Q2 | $77K | Hold |
2,932
| – | – | ﹤0.01% | 2245 |
|
|
2016
Q1 | $73K | Hold |
2,932
| – | – | ﹤0.01% | 2245 |
|
|
2015
Q4 | $103K | Hold |
2,932
| – | – | ﹤0.01% | 2050 |
|
|
2015
Q3 | $63K | Hold |
2,932
| – | – | ﹤0.01% | 2324 |
|
|
2015
Q2 | $80K | Hold |
2,932
| – | – | ﹤0.01% | 2282 |
|
|
2015
Q1 | $90K | Hold |
2,932
| – | – | ﹤0.01% | 2115 |
|
|
2014
Q4 | $97K | Sell |
2,932
-199
| -6% | -$6.48K | ﹤0.01% | 1997 |
|
|
2014
Q3 | $91K | Buy |
+3,131
| New | +$87.3K | ﹤0.01% | 1950 |
|
Legal & General Group's GHDX Position: Q4 2019 in Review
Legal & General Group sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 60,658 shares — an estimated $4.11M sold.
Legal & General Group first reported a position in GHDX in Q3 2014 and held it in 21 quarters. The position peaked at $4.11M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Legal & General Group reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Legal & General Group sold 60,658 Genomic Health, Inc. shares in Q4 2019, an estimated $4.11M.
- Legal & General Group first reported a position in Genomic Health, Inc. in Q3 2014 and held it in 21 quarters.
- Legal & General Group's Genomic Health, Inc. position peaked at $4.11M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Legal & General Group's 13F filing for Q4 2019, filed 13 Feb 2020.